Expanding our opportunities for success

In 2017, we entered into a worldwide agreement with Janssen Biotech, Inc. to co-develop and commercialize PTG-200 for all indications, including IBD. The scope of the collaboration was expanded in 2019 to additionally support efforts towards second generation IL-23 receptor antagonists.

We are open to additional collaborative opportunities involving our other pipeline product candidates. If interested, you can get in touch here.